Evidence map›Paper›PMID 28913657›Full record

ArticleWorld journal of urology2017

Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.

Ross J Mason, Igor Frank, Bimal Bhindi, Matthew K Tollefson, R Houston Thompson, R Jeffrey Karnes, Robert Tarrell, Prabin Thapa, Stephen A Boorjian

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ross J MasonDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.
Igor FrankDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.
Bimal BhindiDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.
Matthew K TollefsonDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.
R Houston ThompsonDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.
Robert TarrellDepartment of Health Sciences Research, Rochester, MN, USA.
Prabin ThapaDepartment of Health Sciences Research, Rochester, MN, USA.
Stephen A BoorjianDepartment of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA. Boorjian.Stephen@mayo.edu.
WinnMed · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate perioperative and oncologic outcomes of patients undergoing radical cystectomy (RC) for recurrence of urothelial carcinoma (UC) after prior partial cystectomy (PC), and to compare these outcomes to patients undergoing primary RC.

methodsPatients who underwent RC for recurrence of UC after prior PC were matched 1:3 to patients undergoing primary RC based on age, pathologic stage, and decade of surgery. Perioperative and oncologic outcomes were compared using Wilcoxon sign-rank test, McNemars test, the Kaplan-Meier method, and Cox proportional hazards regression analyses.

resultsOverall, the cohorts were well matched on clinical and pathological characteristics. No difference was noted in operative time (median 322 versus 303 min; p = 0.41), estimated blood loss (median 800 versus 700 cc, p = 0.10) or length of stay (median 9 versus 10 days; p = 0.09). Similarly, there were no differences in minor (51.7 versus 44.3%; p = 0.32) or major (10.3 versus 12.6%; p = 0.66) perioperative complications. Median follow-up after RC was 5.0 years (IQR 1.5, 13.1 years). Notably, CSS was significantly worse for patients who underwent RC after PC (10 year-46.8 versus 65.9%; p = 0.03). On multivariable analysis, prior PC remained independently associated with an increased risk of bladder cancer death (HR 2.28; 95% CI 1.17, 4.42).

conclusionsRC after PC is feasible, without significantly adverse perioperative outcomes compared to patients undergoing primary RC. However, the risk of death from bladder cancer may be higher, suggesting the need for careful patient counseling prior to PC and the consideration of such patients for adjuvant therapy after RC.

Indexed as

Carcinoma, Transitional CellCystectomyNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsAgedFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedOutcome and Process Assessment, Health CarePostoperative ComplicationsProportional Hazards ModelsRisk AssessmentUnited StatesOutcomesPartial cystectomyRadical cystectomySurvivalUrothelial carcinoma

Identifiers

PMID28913657
OpenAlexW2754590163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.